-
Company: DIMA BIOTECHNOLOGY LTD
-
Contact:
-
Telephone number:
-
Industry: Laboratory
-
Address: Fuchunjiang Rd No. 188, Gaoxin District, Suzhou, Jiangsu, 215163 China
-
E-mail:
-
Company category:
-
Number Of Employees:
-
Website Address:
-
Last updated: 2026-03-23
Taxpayer No:
Revenue:
Company Introduction：
DIMA Biotechnology LLC is a leading biotechnology company specializing in preclinical research and development solutions for the biopharmaceutical industry. We focus on accelerating early-stage drug discovery by providing a comprehensive portfolio of pre-designed, sequence-verified, and functionally validated antibody molecules tailored to the evolving needs of BioPharma companies. With over 5,000 lead antibody molecules targeting approximately 500 druggable targets, our rapidly expanding library enables faster candidate selection and streamlined R&D timelines. We are actively working toward developing lead antibodies for all potential therapeutic targets, reinforcing our commitment to supporting innovation and efficiency in antibody-based drug development. Our technological edge lies in the continued optimization of proprietary platforms that span the full antibody discovery and development pipeline: DiMPro™ Membrane Protein Platform: We are experts in expressing and purifying membrane proteins using mammalian systems. Our inventory includes over 1,000 functional proteins, featuring more than 500 active full-length multi-pass membrane proteins, such as GPCRs and ion channels. We offer five proven expression formats: Membrane Nanoparticles (MNP), Virus-Like Particles (VLP), Exosomes (EXO), Detergent-based extraction, and Nanodiscs. DIMA mAb™ Single B Cell Antibody Discovery Platform: This high-throughput discovery platform enables the rapid generation of over 10,000 positive antibody hits within a month. It efficiently delivers diverse, fully sequence-defined monoclonal antibodies with high functional relevance. DiLibrary™ Mammalian Display Antibody Engineering Platform: Our proprietary engineering system supports key antibody optimization processes such as humanization and affinity maturation. Antibodies developed using DiLibrary™ exhibit enhanced developability compared to traditional phage or yeast display methods. DiAssay™ Antibody Evaluation Platform: This platform supports customized screening and functional assessment, enabling identification of optimal hit molecules for a range of therapeutic modalities, including Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and CAR-T therapies. At DIMA Biotechnology, we are driven by a mission to empower the BioPharma community with high-quality, innovative solutions that shorten development cycles and accelerate the creation of transformative therapies.
Products：
